Stable State Proadrenomedullin Level in COPD Patients: A Validation Study

References

• Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063):1436–1442.
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006; 61(3):250–258.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133(1):14–20.
   PubMed Web of Science ®Google Scholar
• Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82(1):53–59.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121(5):1434–1440.
   PubMed Web of Science ®Google Scholar
• Cote CG, Casanova C, Marin JM, Lopez MV, Pinto-Plata V, de Oca MM, et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008; 31(3):571–578.
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167(4):544–549.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11):925–931.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, Casanova C, Montes de OM, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Puhan MA, Garcia-Aymerich J, Frey M, ter RG, Anto JM, Agusti AG, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374(9691):704–711.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Muller C, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134(2):263–272.
   PubMed Web of Science ®Google Scholar
• Zuur-Telgen MC, Brusse-Keizer MG, Vandervalk PD, van der Palen J, Kerstjens HA, Hendrix MG. Stable state MR-proadrenomedullin level is a strong predictor for mortality in COPD patients. Chest 2013.
   PubMedGoogle Scholar
• Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the “BODE-A” index. Eur Respir J 2014; 43(2):397–408.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med 2015; 53(4):521–539.
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005; 146(6):2699–2708.
   PubMed Web of Science ®Google Scholar
• Yoshibayashi M, Kamiya T, Kitamura K, Saito Y, Kangawa K, Nishikimi T, et al. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol 1997; 79(11):1556–1558.
   PubMed Web of Science ®Google Scholar
• Cheung BM, Hwang IS, Li CY, WS O, Tsang KW, Leung RY, et al. Increased adrenomedullin expression in lungs in endotoxaemia. J Endocrinol 2004; 181(2):339–345.
   PubMed Web of Science ®Google Scholar
• Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994; 338(1):6–10.
   PubMed Web of Science ®Google Scholar
• Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004; 25(8):1369–1372.
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51(10):1823–1829.
   PubMed Web of Science ®Google Scholar
• Zuur-Telgen MC, Brusse-Keizer MG, van der Palen J, Vandervalk PD, Kerstjens HA, Hendrix MG. Response. Chest 2014; 146(2):e65–e66.
   Google Scholar
• Khorfan R. Usefulness of midrange-proadrenomedullin as a predictor of mortality in patients with COPD. Chest 2014; 146(2):e65.
   Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/. 2011.
   Google Scholar
• Telgen MC, Brusse-Keizer MG, van der Valk P, van der Palen J, Kerstjens HA, Hendrix MG. Impact on clinical decision making of quality control standards applied to sputum analysis in COPD. Respir Med 2011; 105(3):371–376.
   PubMed Web of Science ®Google Scholar
• Jougasaki M, Burnett JC, Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000; 66(10):855–872.
   PubMed Web of Science ®Google Scholar
• vonHaehling S., Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010; 12(5):484–491.
   PubMed Web of Science ®Google Scholar
• Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, et al. Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med 2008; 46(2):204–211.
   PubMed Web of Science ®Google Scholar
• Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007; 49(14):1525–1532.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93(3):580–586.
   PubMed Web of Science ®Google Scholar
• Koehorst-Ter HK, Kort S, van der Palen J, van Beurden WJ, Movig KL, van d V, et al. Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related. Int J Chron Obstruct Pulmon Dis 2016; 11:1679–1688.
   PubMed Web of Science ®Google Scholar
• Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012; 39(5):1144–1155.
   PubMed Web of Science ®Google Scholar
• Nam B-H, D'Agostino R the area under the ROC curve. In Huber-Carol C, Balakrishnan N, Nikulin MS, Mesbah M, eds. Goodness-of-fit tests and model validity. Boston: Birkhäuser, 2002; 273–277.
   Google Scholar
• Brusse-Keizer M, Zuur-Telgen M, van der Palen J, VanderValk P, Kerstjens H, Boersma W, et al. Adrenomedullin optimises mortality prediction in COPD patients. Respir Med 2015; 109(6):734–742.
   PubMed Web of Science ®Google Scholar
• Albrich WC, Ruegger K, Dusemund F, Schuetz P, Arici B, Litke A, et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J 2013; 42(4):1064–1075.
   PubMed Web of Science ®Google Scholar
• Grolimund E, Kutz A, Marlowe RJ, Vogeli A, Alan M, Christ-Crain M, et al. Long-term prognosis in COPD exacerbation: role of biomarkers, clinical variables and exacerbation type. COPD 2015; 12(3):295–305.
   PubMedGoogle Scholar